A cell line is a cell culture that has been established for a long time and continues to proliferate in fresh medium. Cell line development is used to test drug discovery efficiency and toxicity. It is needed to make recombinant proteins such as chemotherapy drugs, bi-specific biologics, cell proliferation, and enzymatic utilization of a range of expression methods. Cell lines save time, effort, and money by giving high-yield cells that may be utilized for in vitro testing, lowering the risk of a research medication failing during the clinical trial stage.
Request for the trending sample of this report:
To propel the cell line development market forward, new therapies are being developed. The creation of cell lines has a wide range of applications. Cell line development is used extensively in the development of immunotherapy for cancer treatment. According to a World Health Organization factsheet from 2018, cancer is the world’s second largest cause of mortality, accounting for 9.6 million deaths in 2018. Owing to its specificity and efficacy, pharmaceutical and biotech firms are concentrating on creating new treatments such as immunotherapy. By delivering a high output of monoclonal antibodies, cell line development aids in the accelerating of the drug discovery process and the modification of drug testing, which is projected to drive the global cell line development market forward.
The global cell line development market is projected to increase due to growing technical developments in the field. Lonza Group introduced Multiplex Cell line culture utilizing GS Xceed Gene Expression System in November 2017, which aids in evaluating numerous drug candidates at an early stage of development, saving four to six months that would otherwise be required in traditional development.
Due to significant expenditure by pharmaceutical firms in creating a unique study conducted and rising off patenting of key goods, which would boost biosimilar medicine development, North America is projected to maintain the dominating position in the global cell line development market. Owing to the high number of drugs going off-patent and medical services reforms favoring generic medicine progressions, U.S. generic drug sales totaled US$ 70 billion in 2015, accounting for about 25% of the global market, according to a 2016 report by the International Trade Administration of the Department of Commerce (USA). Biologics account for more than a third of all novel medicines in clinical trials or awaiting FDA clearance, according to the same research. According to the Pharmaceutical Research and Manufacturers of America, businesses in the United States such as Novartis AG, Merck and Company, and F. Hoffmann-La Roche AG invested a total of US$ 75 billion on R&D activities.
Cell line development firms are collaborating with drug discovery companies to accelerate the growth of the global cell line development market.
Request PDF Brochure Report –
Major companies contributing in the global cell line development market are Thermo Fisher Scientific, Inc., Selexis SA, American Type Culture Collection, Wuxi App Tec, Inc., Sigma-Aldrich Corporation, Goodwin Biotechnology Inc., Lonza Group AG, Cleancells, Sartorious AG, Corning, Inc., European Collection of Cell Cultures, GE Healthcare, and PX’Therapeutics SA.
Turgut Pharmaceuticals and Selexis SA announced a third advertising licensing deal in December 2017 that would give Turgut direct exposure to Selexis’ SUREtechnology Platform and SURE CHO-M Cell Line for the advancement of biosimilar products for the treatment of two rare diseases: paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The businesses had earlier agreed (in July 2016) to use the SURE CHO-M Cell Lines to create biosimilar medicines to treat inflammatory disorders and malignancies.
CBMG and GE Healthcare announced a cooperation in April 2017 to produce stem cells for cell line creation.
PX’Therapeutics established a cooperation with biotech business Advaxis in January 2018 for the systems integration of Advaxis immunotherapies.
Denali Therapeutics and Lonza partnered in February 2018 to research and manufacture biologic therapeutics utilizing Lonza’s GS Xceed cell line development technology.
Manufacturing firms are concentrating on diversifying their company portfolios in order to strengthen their brand reputation and grow their customer base. Lonza and Sanofi formed a strategic collaboration in February 2017 with the goal of establishing mammalian cell facilities in Switzerland to generate monoclonal antibodies.
Reasons to Purchase this Report
Current and future of global Cell Line Development market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
Cell Line Development Market Taxonomy
On the basis of Product type:
- Reagents & Media
On the basis of source:
On the basis of cell line:
- Continuous Cell Line
- Primary Cell Line
On the basis of application:
- Drug Discovery
- Toxicity Testing
- Tissue Engineering
On the basis of end user:
- Pharmaceutical companies
- Research and Academic Institution
On the basis of Region:
- North America
- Latin America
- Asia Pacific
- Middle East
he content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cell Line Development product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Cell Line Development , with price, sales, revenue and global market share of Cell Line Development in 2018 and 2020.
Chapter 3, the Cell Line Development market trends competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cell Line Development breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2020.
Chapter 12, Cell Line Development market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Cell Line Development sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027